18 results about "INKT Cells" patented technology

The invention relates to the technical field of cell biology, in particular to an iNKT cell cryopreservation solution and a method for cryopreserving iNKT cells by using the cryopreservation solution. The invention provides an immune cell cryopreservation solution. The immune cell cryopreservation solution comprises human serum albumin, a basic low-temperature protection solution and an optional human platelet lysate. The immune cell freezing medium does not contain animal-derived components except for human bodies, and has the advantages of simple components and good stability. According to the cryopreservation liquid disclosed by the invention, through the combined action of the basic low-temperature protection liquid (such as CryoStor10 (CS10)) and the human serum albumin, the motility rate after cell recovery is improved, and the damage to immune cells (such as iNKT) in the cryopreservation process is reduced. After a small amount of human platelet lysate is further added, the survival rate of cell resuscitation and the amplification capacity can be further improved.

We have discovered that allogeneic HSC-engineered human iNKT (3rdHSC-iNKT) cells display potent anti-GvHD functions, by eliminating antigen-presenting myeloid cells in vitro and in xenograft models, without negatively impacting tumor eradication by allogeneic T cells in preclinical models of lymphoma and leukemia. The 3rdHSC-iNKT cells closely resembled the CD4−CD8− / + subsets of endogenous human iNKT cells in phenotype and functionality. Embodiments of the invention harness these discoveries in new methods and materials for alleviating graft versus host disease.

The present application discloses a screening method for tumor immunotherapy reagents targeting Vam6, which comprises administering a candidate reagent to iNKT cells, and treating the iNKT cells with and without the reagent with an iNKT cell activator, and measuring the expression level of Vam6 of the iNKT cells, wherein a decrease or increase in the expression level of Vam6 of the iNKT cells administered with the candidate reagent compared with the iNKT cells without the candidate reagent indicates that the candidate reagent is a potential tumor immunotherapy reagent targeting Vam6. The present application also discloses a method for screening reagents for enhancing the anti-tumor function of iNKT cells using the screening method, and a pharmaceutical composition for treating tumors, which comprises the screened candidate reagent, and a kit comprising the pharmaceutical composition.

The present disclosure relates to compositions comprising constant natural killer T (iNKT) cells, and methods of treating cancer using the compositions comprising the iNKT cells.

The invention provides a method for in-vitro amplification and induced activation of iNKT cells, and belongs to the technical field of immune cell preparations. The in-vitro amplification method comprises the following steps: S1, separating peripheral blood PBMCs cells; s2, adding a part of PBMCs into a culture medium I for stimulation culture and irradiation, and separating to obtain irradiated PBMCs; s3, re-suspending the other part of PBMCs cells in a culture medium II, adding alpha-GalCer and IL-2 to stimulate culture, then adding the irradiated PBMCs cells, and amplifying iNKT cells; the induction and activation method comprises the following steps: amplifying the iNKT cells, adding a culture medium III, adding a dasatinib derivative, and inducing the iNKT cells to be mature. According to the method, amplification and induced activation of the iNKT cells can be rapidly promoted, the amplification efficiency is high, the obtained iNKT cells are high in cytotoxicity, the method is safe, and graft versus host reaction is not caused.

Lipid nanoparticles (LNP) having an immune regulation function, presenting at least one immune ligand on the surface thereof, promoting activation of non-variant natural killer T cells (iNKT cells) and inducing an immune response, or mediating recognition, binding or internalization between the lipid nanoparticles and the immune cells, and regulating the functional state of the immune cells; the formulation of the lipid nanoparticles comprises at least one of a ceramide-based glycolipid family, a peptidomimetic, and fucosterol, and the formulation forms nanoparticles of 1-1000 nm by a mixing process. The invention provides a lipid nanoparticle formula for enhancing organ targeting, cell targeting or cell activity, a pharmaceutical composition prepared by using the formula and application of the pharmaceutical composition. The formulation can encapsulate and deliver active ingredients such as nucleic acids, gene editing system components and natural small molecules.

The invention relates to immunotherapy, and to invariant natural killer T (iNKT) cells, and iNKT cell immunotherapy. The invention concerns CAR-iNKT cell immunotherapy, in particular, mono- and bi-specific CAR-iNKT cell immunotherapy, as well as pharmaceutical compositions comprising these iNKT cells, and to their use in therapy, as well as therapies and methods for treating, preventing, or ameliorating cancer or infection. The invention also concerns the treatment of various leukaemias, such as acute lymphoblastic leukaemia (ALL), including infant ALL.

The present disclosure is based at least in part on the discovery of novel BCMA antibodies or antigen-binding fragments thereof, and generally, genetically modified cells (e.g., iNKT cells, CAR T cells, etc.) expressing chimeric antigen receptors comprising anti-BCMA antibodies or antigen-binding fragments thereof exhibit improved properties, including increased binding to BCMA, killing of BCMA-expressing cancer cells in vitro and in vivo, and enhanced persistence in treated subjects.

This invention relates to invariant natural killer T (iNKT) cells, and particularly, but not exclusively, to iNKT cell adaptors or fusion proteins that specifically bind to iNKT cells. The invention also relates to nucleic acids encoding such iNKT cell adaptors, novel pharmaceutical compositions comprising these adaptors, and their use in treatment, as well as therapies and methods for treating, preventing, or improving cancer.

The present disclosure relates to compositions comprising allogeneic invariant natural killer T (iNKT) cells, including allogeneic iNKT cell adjuvants, and methods of using the compositions comprising the iNKT cells for treatment of diseases and conditions, including cancer.

A chimeric ILT receptor (CIR) is provided, which comprises a targeting region from ILT2 or ILT4, a transmembrane domain, and an intracellular domain (ICD). The ICD includes a signal transduction region (e.g., CD3 zeta (CD3 zeta), DAP10, DAP12), and optionally a co-stimulatory region (e.g., MyD88, TIR domain, etc. Also provided are nucleic acids (e.g., expression vectors) encoding the subject CIR, and genetically modified cells (e.g., immune cells, such as NK cells, NK-T cells, T cells, iNKT cells, macrophages, etc.) expressing the subject CIR.

The application belongs to the technical field of biological medicine, and particularly relates to an iNKT cell agonist and angelica polysaccharide adjuvant composition, a preparation method and application thereof. The vaccine combined adjuvant is composed of angelica polysaccharide and iNKT cell agonist, wherein the angelica polysaccharide is a uniform polysaccharide component obtained through water extraction, alcohol precipitation, deproteinization, decolorization, dialysis and chromatographic purification, and the weight average molecular weight is 346628 Da; the mass ratio of the angelica polysaccharide to the iNKT cell agonist is 200-500 ug:2-5 ng. The application also provides application of the vaccine combined adjuvant in preparation of a vaccine. Compared with the angelica polysaccharide or the iNKT cell agonist alone, the combined adjuvant provided by the application can synergistically enhance antigen-specific humoral immune and cellular immune responses, improve the immune effect of the vaccine, and has the advantages of simple preparation process, good stability and wide application prospect.

The present disclosure, at least in part, is based on the discovery of novel anti-Fibroblast activation protein (FAP) antibodies or antigen binding fragments thereof, and genetically modified cells (e.g., iNKT cells) expressing chimeric antigen receptors comprising the anti-FAP antibody or antigen binding fragment thereof demonstrate improved properties, including increased binding to FAP, killing of FAP-expressing cancer cells in vitro and in vivo; and enhanced persistent in a subject receiving the therapy.

The application discloses a polyvanadic acid-based complex with anti-obesity and obesity-related inflammation reduction and a preparation and application thereof. Glucosamine hexavanadate is mixed with a functional food additive to prepare the polyvanadic acid-based complex. The polyvanadic acid-based complex can significantly reduce the weight of mice, especially reduce fat tissue accumulation and inflammation at the fat tissue site. The polyvanadic acid-based complex can reduce the accumulation of macrophages in the fat tissue of mice, enhance the iNKT cell function of HFD mice, and reduce the number of proinflammatory factors, thereby reducing the whole-body fat tissue inflammation of HFD mice.

The invention discloses a culture method of iNKT cells, and belongs to the technical field of cell culture. The culture method comprises the following steps: firstly taking human peripheral blood, extracting PBMC, pre-activating the PBMC, then carrying out directional culture on the pre-activated PBMC, then obtaining high-purity iNKT cells through a magnetic adsorption method, and finally carrying out multiplication culture on the high-purity iNKT cells. The iNKT cell obtained by the invention has the characteristics of high purity, high amplification multiple, high motility rate and low function depletion degree.

The application provides a method for in-vitro expansion and induced activation of iNKT cells, and belongs to the technical field of immune cell preparations. The in-vitro expansion method comprises the following steps: S1, separating peripheral blood PBMCs cells; S2, adding a part of the PBMCs cells into culture medium I for stimulation culture, irradiation, and separation to obtain the irradiated PBMCs cells; and S3, resuspending another part of the PBMCs cells in culture medium II, adding alpha-GalCer and IL-2 for stimulation culture, then adding the irradiated PBMCs cells to expand the iNKT cells. The induced activation method comprises the following steps: after the iNKT cells are expanded, adding culture medium III and a dasatinib derivative to induce maturation of the iNKT cells. The method can quickly promote expansion and induced activation of the iNKT cells, has high expansion efficiency, and the obtained iNKT cells have high cytotoxicity; in addition, the method is safe and does not cause a graft-versus-host reaction.

The invention relates to a method for preparing iPSC and differentiating the iPSC into iNKT cells. The method comprises the following steps: (1) introducing a reprogramming induction factor into the iNKT cells, and then reprogramming; (2) culturing the reprogrammed cells to obtain iPSCs, in which the culturing process comprises: (a) culturing the reprogrammed cells in a culture medium comprising basic fibroblast growth factor (bFGF), and (b) culturing the reprogrammed cells in a culture medium comprising an antioxidant, a glycogen synthase kinase 3 (GSK-3) inhibitor, a ROCK inhibitor, and a histone deacetylase (HDAC) inhibitor; and (3) differentiating the iPSCs into the iNKT cells.

The present application provides a MSLN-containing chimeric antigen receptor, iNKT cells transduced by the chimeric antigen receptor and use of the chimeric antigen receptor and the INKT cells in treatment of liver cancer, particularly cholangiocarcinoma. The present application utilizes the characteristic that iNKT cells can home and colonize the liver, and selects a proper MSLN antibody sequence, thereby realizing high tumor killing efficiency and CAR-iNKT cell proliferation speed; the Anti-MSLN CAR-INKT cell can effectively infiltrate into the liver tumor part, greatly improve the curative effect, reduce the recurrence and alleviate the toxic and side effects.